SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours - PubMed (original) (raw)

Review

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

J M Brown. Br J Cancer. 1993 Jun.

Free PMC article

Abstract

SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy and chemotherapy. Finally, the major unanswered questions on the drug are outlined.

PubMed Disclaimer

Similar articles

• Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
  Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M, et al. Monge A, et al. J Med Chem. 1995 May 12;38(10):1786-92. doi: 10.1021/jm00010a023. J Med Chem. 1995. PMID: 7752202
• Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
  Minchinton AI, Brown JM. Minchinton AI, et al. Br J Cancer. 1992 Dec;66(6):1053-8. doi: 10.1038/bjc.1992.409. Br J Cancer. 1992. PMID: 1457345 Free PMC article.
• SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
  Brown JM, Lemmon MJ. Brown JM, et al. Radiother Oncol. 1991;20 Suppl 1:151-6. doi: 10.1016/0167-8140(91)90203-s. Radiother Oncol. 1991. PMID: 2020764
• Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
  Brown JM. Brown JM. Br J Cancer. 1998 Jun;77 Suppl 4(Suppl 4):12-4. doi: 10.1038/bjc.1998.430. Br J Cancer. 1998. PMID: 9647614 Free PMC article. Review.
• Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
  Denny WA, Wilson WR. Denny WA, et al. Expert Opin Investig Drugs. 2000 Dec;9(12):2889-901. doi: 10.1517/13543784.9.12.2889. Expert Opin Investig Drugs. 2000. PMID: 11093359 Review.

Cited by

• Role of the tumor microenvironment in the lymphatic metastasis of cervical cancer (Review).
  Wang L, Yi S, Teng Y, Li W, Cai J. Wang L, et al. Exp Ther Med. 2023 Sep 1;26(4):486. doi: 10.3892/etm.2023.12185. eCollection 2023 Oct. Exp Ther Med. 2023. PMID: 37753293 Free PMC article. Review.
• Companion Animals as a Key to Success for Translating Radiation Therapy Research into the Clinic.
  Vanhaezebrouck IF, Scarpelli ML. Vanhaezebrouck IF, et al. Cancers (Basel). 2023 Jun 27;15(13):3377. doi: 10.3390/cancers15133377. Cancers (Basel). 2023. PMID: 37444487 Free PMC article. Review.
• Glutamine metabolism and radiosensitivity: Beyond the Warburg effect.
  Alden RS, Kamran MZ, Bashjawish BA, Simone BA. Alden RS, et al. Front Oncol. 2022 Nov 17;12:1070514. doi: 10.3389/fonc.2022.1070514. eCollection 2022. Front Oncol. 2022. PMID: 36465373 Free PMC article. Review.
• Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.
  Zhou R, Zhao D, Beeraka NM, Wang X, Lu P, Song R, Chen K, Liu J. Zhou R, et al. Metabolites. 2022 Oct 5;12(10):943. doi: 10.3390/metabo12100943. Metabolites. 2022. PMID: 36295845 Free PMC article. Review.
• The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.
  Gallez B. Gallez B. Front Pharmacol. 2022 Jul 15;13:853568. doi: 10.3389/fphar.2022.853568. eCollection 2022. Front Pharmacol. 2022. PMID: 35910347 Free PMC article. Review.

References

1. 1. J Natl Cancer Inst. 1992 Feb 5;84(3):187-93 - PubMed
2. 1. Br J Cancer. 1990 May;61(5):722-6 - PubMed
3. 1. Biochem Pharmacol. 1992 Jul 22;44(2):251-9 - PubMed
4. 1. Cancer Res. 1992 Aug 15;52(16):4473-7 - PubMed
5. 1. Br J Cancer. 1993 Feb;67(2):321-5 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal